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ABSTRACT
The use of a mismatched allograft necessitates T cell depletion for prevention of uncontrolled graft-versus-
host disease (GVHD), thus impairing a graft-versus-leukemia effect. Data on donor lymphocyte infusion (DLI)
after mismatched stem cell transplantation are lacking. Our experience with 28 patients (treated with 59
mismatched DLIs; range, 1-7) is described. The procedure was prophylactic in 6 patients (9 DLIs) and
therapeutic in 22 (50 DLIs). DLI dose ranged from 102 to 1.5  109 T cells/kg. In the 6 patients receiving
prophylactic DLI, complete remission was maintained in 5; however, 2 died from GVHD. Clinical response to
therapeutic DLI was seen in 6 of 22 (27.3%) patients; a greater tumor burden produced a lower response.
GVHD appeared in 13 of 28 patients. Surprisingly, a greater HLA mismatch was associated with a lower risk
of GVHD, with 3 of 19 DLIs in 3/6 matching and 16 of 29 DLIs in 5/6 matching with similar follow-up.
Nevertheless, no correlation between efficacy and HLA mismatching was noted. Death was frequent and
usually related to the basic disease rather than to DLI complications. We conclude that mismatched DLI is
feasible and may be effective, especially if given soon after transplantation. Future developments using cell
therapy with selective or targeted anticancer activity are warranted, with special attention to prophylactic
treatment of T cell depleted mismatched allografts recipients.
© 2006 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
The aim of allogeneic stem cell transplantation
SCT) is to combine tumor cytoreduction with opti-
al doses of chemoradiotherapy and to replace host
ith donor immunohematopoietic cells. Induction of
ost-versus-graft tolerance by engraftment of donor
tem cells enables durable engraftment of immuno-
ompetent donor lymphocytes, with subsequent in-
uction of graft-versus-leukemia (GVL) effects ex-
ected to eliminate all residual chemoradiation-
esistant malignant cells of host origin by alloreactive
onor cells. For patients with no matched sibling
vailable, a matched unrelated donor may provide an
lternative treatment option. However, despite the
rowing number of volunteers in matched unrelated Ganks, for a large number of patients in need, a donor
annot be found and/or the search process is too long
1]. Successful use of a haploidentical mismatched
amily member donor may provide a donor for every
atient in need at an optimal timing. As the technol-
gy improves and experience increases, the number of
atients undergoing successful SCT from a mis-
atched related donor increases [2]. The use of a
ismatched donor usually necessitates T cell deple-
ion or positive selection of stem cells to prevent
ncontrolled graft-versus-host disease (GVHD) [3].
andatory T cell depletion increases the risk of graft
ejection due to loss of engraftment facilitating lym-
hocytes and decreases the intensity and efﬁcacy of a
VL effect. Data on add back of donor lymphocyte
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R. Or et al.1296nfusion (DLI) after mismatched SCT done to correct
hese problems are lacking. We present our cumula-
ive experience using DLI in a group of 28 recipients
f mismatched allografts, with particular attention to
he efﬁcacy and toxicity.
ETHODS
Twenty-eight high-risk patients with hematologic
alignancies that were treated with mismatched stem
ell allografts followed by DLIs are described. Indica-
ions for transplantation and disease status are pre-
ented in Table 1, and tumor burden deﬁnitions are
isted in Table 2. Patients were included if they had an
ndication for DLI after HLA-mismatched SCT with-
ut active GVHD, were off cyclosporine, and con-
ented to participate in the clinical trial. Fifteen male
nd 13 female patients, with an range of 4 to 63 years
median, 21 years), participated. All patients were re-
erred to the Hadassah Hospital (Jerusalem, Israel) for
CT between 1995 and 2003. Each participant signed
n approved informed consent form. Fifteen patients
eceived transplants from a parent, 9 from a sibling, 2
rom unrelated donors (UDs), and 2 from other do-
ors (Table 3). All DLIs were given from the original
onor. Twelve patients received transplants from a
/6 HLA-matched donor, 5 from a 4/6 HLA-matched
onor, and 11 from a 5/6 HLA-matched donor. HLA
yping method differed among family members serving
s donors or UDs. In case of family donors, HLA-A and
B were typed using serologic methods and HLA-DR
as typed using molecular methods. If matching higher
hen 4/6 was found, matched antigens were typed by
olecular methods. In UDs, HLA-A, -B, and -DR were
yped using molecular methods.
Conditioning used in most patients (n  19) was a
udarabine-based myeloablative regimen. Other con-
itioning regimens were a ﬂudarabine-based nonmy-
loablative regimen (n 3), a cyclophosphamide/total
able 1. Demographic Data of Mismatched DLI-Treated Patients
iagnosis n patients
Acute myeloid leukemia 13
Acute lymphoblastic leukemia 7
Chronic myeloid leukemia 5
Other 3
Hodgkin disease 1
Non-Hodgkin lymphoma 1
Myelodysplastic syndrome 1
ndication for DLI n procedures
Prophylactic DLI (tumor burden 0) 9
Therapeutic DLI (tumor burden 1-4) 50
1 0
2 9
3 26
4 17LI indicates donor lymphocyte infusion.ody irradiation-based myeloablative regimen (n 4),
nd a busulfan myeloablative regimen (n 2). GVHD
rophylaxis used in patients with 5/6 HLA matching
onsisted of cyclosporine with/without methotrexate.
n patients with lower matching, GVHD prophylaxis
as done using T cell depletion.
The method of donor harvesting for DLI de-
ended on the quantity considered necessary. In cases
f low-dose DLI (106 T cells/kg), peripheral blood
as used. High-dose DLI (106 T cells/kg) was col-
ected by leukapheresis using the Cobe (Gambro
CT, Lakewood, CO) spectra cell separator. T cell
uantity in the graft was estimated by measuring the
otal number of lymphocytes in the graft multiplied by
.7 (representing the average T cell proportion in pe-
ipheral blood). DLI dose and frequency differed ac-
ording to HLA disparity, chimeric state, and disease
ctivity. Basic dosing schedule was 4-6 weeks if grade1
VHD did not appear and an indication for DLI still
xisted. DLI for patients without evidence of disease
tumor burden, 0) was deﬁned as prophylactic, whereas
LI for patients with evidence of disease (tumor burden,
-4) was deﬁned as therapeutic (Table 2). DLI effective-
ess was deﬁned as induction of remission.
Acute and chronic GVHD types were graded ac-
ording to severity indices of the International Bone
arrow Transplantation Registry [4]. Immediately af-
er the appearance of signs and symptoms of acute
VHD grade 2, intravenous methylprednisolone
2 mg/kg) was administered. Cyclosporine was added
nly if no control of GVHD could be achieved by
ethylprednisolone.
able 2. Deﬁnition of Tumor Burden
Tumor
Burden Definition
0 Complete remission, CML chronic phase
1 Molecular relapse
2 Cytogenetic relapse
3 Hematologic relapse, CML blastic/accelerated phase
4 Primary resistance to BMT
ML indicates chronic myeloid leukemia; BMT, bone marrow
transplantation.
able 3. Donor and HLA Matching Data
Patients, n
onor relationships
Parent 15
Sibling 9
Unrelated 2
Child 1
Uncle 1
egree of match
3/6 HLA Antigens 12
4/6 HLA Antigens 5
5/6 HLA Antigens 11
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Mismatched DLI after SCT 1297To assess degree of chimerism, minimal residual
isease, and early relapse, patients were monitored at
egular intervals by cytogenetic analysis and by donor-
nd host-speciﬁc DNA markers using male and female
melogenin gene polymerase chain reaction bands [5]
nd by variable number of tandem repeats/polymerase
hain reaction assay [6].
Relapse was deﬁned as recurrence of hematologic
alignancy after the initial achievement of complete
emission (CR). In patients who did not achieve re-
ission of disease after transplantation, day 1 was
onsidered for analysis as the day of relapse.
Mortality analysis was done with respect to the
rst DLI event, and GVHD analysis was done with
espect to each DLI regardless of other DLIs given to
he same patient. Statistical analysis included the
ann-Whitney test and Fischer exact test.
ESULTS
LI Procedures
Fifty-nine DLIs were given to 28 patients at dif-
erent intervals after SCT. The median time from
CT to DLI was 109 days (range, 1-984 days). Nine
rocedures were prophylactic for 6 patients with re-
istant overt disease at time of transplantation (but in
R at time of DLI, including 3 patients with chronic
yeloid leukemia [CML], 2 with acute myeloid leu-
emia [AML], and 1 with myelodysplastic syndrome)
nd 50 were therapeutic for treatment of relapse (Ta-
le 2). Time from transplantation to relapse was 1-361
ays (median, 83 days). Most patients had documented
ull (n  16) or partial (n  6) donor cell engraftment
efore DLI. Thirteen patients received 1 DLI
range, 1-7 DLIs; median, 1 DLI/patient). DLI dose
anged from 102 to 1.5  109 calculated T cells/kg
median, 1  107 calculated T cells/kg). In principle,
ower doses were given to patients with a lesser tumor
urden, whereas higher doses were given to patients
ith a greater tumor burden (Table 2).
LI Efficacy
Six patients received prophylactic DLIs (HLA
atching 3/6 in 4 patients, 4/6 in 1 patient, and 5/6 in
patient). Only 1 patient relapsed and 3 of them are
live in continuous CR.
Therapeutic DLIs were given to 7 patients with
umor burden 4, 12 patients with tumor burden 3, and
patients with tumor burden 2. Clinical response to
LI was seen in 6 of 22 (27.3%) patients including
hose in CR (n  4), those with a hematologic re-
ponse (n  1), and those in partial remission (n  1;
able 4). Three of the 22 patients who received ther-
peutic DLIs survived to time of analysis, 1 with
umor burden 4 and 2 with tumor burden 3. Only 1 of
hese patients is in continuous CR. Cause of death was rainly due to disease progression. GVHD-related
ortality is reported below.
ole of Mismatched DLI on GVHD
Thirteen of 28 patients had GVHD before DLI
median peak grade, 2; range, 1-3); in most cases,
VHD subsided before DLI.
After DLI, signs of acute GVHD appeared after
0 of 59 DLI procedures and in 2 cases (7 DLI
rocedures) clinical features of chronic GVHD were
pparent. The median acute GVHD grade was 2
range, 1-4; Table 4). Time from DLI to onset of
linically overt GVHD ranged from 7 to 155 days
median, 27 days). GVHD was observed after 3 of 19
LI procedures among recipients of 3/6 mismatched
llografts, 1 of 11 DLI procedures among recipients of
/6 mismatched allografts, and 5 of 6 DLI procedures
mong recipients of 5/6 mismatched allografts (P 
002; median follow-ups, 187, 299, and 192 days, re-
pectively). Risk of GVHD development was higher
ith prophylactic DLI (66.7%) than with therapeutic
LI (28.0%; median follow-ups, 630 and 94 days,
espectively; P  .03). In addition, greater tumor bur-
en lowered the risk of GVHD, with 3 of 7 cases
bserved among DLI recipients treated for grade 2
umor burden and 10 of 26 and 1 of 17 cases observed
mong patients with tumor burdens of 3 and 4, re-
pectively (P  .007). Using the Mann-Whitney test,
o correlation was found between the dose of DLI and
he appearance of GVHD. No correlation to GVHD
as found when a cutoff level of 105 calculated T
ells/kg was used. There was no signiﬁcant effect of
R mismatch on the appearance of GVHD.
rocedure-Related Mortality
At the time of analysis, 22 patients died and 6 were
live. Median follow-up from the ﬁrst DLI was 41
ays (range, 7-1629 days). Survivors were 3 of 5 pa-
ients with CML, 2 of 13 patients with AML, and 1 of
patients with acute lymphoblastic leukemia (ALL;
 .033). The patient with ALL was alive but with
ctive disease at time of analysis. Cause of death in 2
atients with CML was related to DLI complications,
hereas only 1 of 11 patients with AML and no
atients with ALL died from DLI complications (P 
017). Cause of death for the remaining patients was
elated to disease progression. No signiﬁcant differ-
nce in mortality was found within the different HLA
atching groups (Figure 1). However, when the
nterval between DLI to death within different
LA-mismatched groups was analyzed, we found
hat a greater degree of mismatch shortened sur-
ival after DLI, with 27, 53, and 132 days for re-
ipients with 3/6, 2/6, and 1/6 HLA mismatching,
espectively (P  .033). Three of the 6 patients who
eceived prophylactic DLI survived, whereas 19 of 22
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R. Or et al.1298atients treated with therapeutic DLI died (P  .09).
he Mann-Whitney test showed only a trend toward
igniﬁcance, with a higher dose of DLI increasing risk
f death (P .103). Using 105 calculated T cells/kg as
able 4. Patients’ Disease Status, DLI Treatment, and Response
UPN
Basic
disease
HLA
match DLI indication DLI doses
1169 CML 3 Prophylactic 104
1462 AML 3 Prophylactic 104
1747 AML 3 Prophylactic 7.6  104, 1.9  106
1777 MDS 3 Prophylactic 1.7  106, 2.45  107
1336 CML 4 Prophylactic 105
1138 CML 5 Prophylactic 5.6  108, 105, 2  1
941 AML 3 Resistant 1.6  107
1055 AML 3 Relapse 103, 103
1068 AML 3 Relapse 4.3  107
1122 ALL 3 Relapse 5  107
1153 AML 3 Relapse 106
1514 ALL 3 Resistant 106, 106
1773 AML 3 Resistant 8.2  105
1874 AML 3 Resistant 104, 3.4  106, 2.5 
1126 AML 4 Relapse 105
1350 ALL 4 Resistant 9  105, 3.6  107, 2
1587 ALL 4 Relapse 102, 104, 107
1813 ALL 4 Relapse 106
930 AML 5 Relapse 105
950 HD 5 Relapse 1.4  107
957 AML 5 Relapse 2  106
1036 CML 5 Relapse 3.2  108
1374 AML 5 Relapse 1.78  107, 3.14  10
1517 ALL 5 Relapse 3.27  107
1599 AML 5 Relapse 3.1  108
1595 NHL 5 Persistent 1.57  107, 108, 108
1607 CML 5 Relapse 1.1  106, 5.6  107,
107, 5.2  107, 106
1757 ALL 5 Relapse 8.8  107, 1.53  109
107, 1.05  109
LI indicates donor lymphocyte infusion; UPN, unique patient nu
chronic myeloid leukemia; AML, acute myeloid leukemia; MD
igure 1. Survival curves calculated by the Kaplan-Meier method
romparing results with different HLA matches (P  .56).cutoff again produced only a trend toward higher
isk of death (P  .09).
ISCUSSION
Allogeneic SCT represents an important thera-
eutic tool for the treatment of an otherwise incurable
road spectrum of malignant and nonmalignant dis-
ases. Preclinical and clinical studies have indicated
hat much more effective eradication of a host immu-
ohematopoietic system or malignant cells can be
ediated by alloreactive donor lymphocytes in the
rocess of adoptive allogeneic cell therapy after SCT
7-9]. Thus, eradication of all malignant cells can be
ccomplished despite complete resistance of such tu-
or cells to maximally tolerated doses of chemoradio-
herapy [10,11]. The major risk of DLI is the devel-
pment of acute and chronic GVHD types that may
ccur in 20%-60% of patients [11-13], leading to
igniﬁcant morbidity and mortality even after treat-
ent with fully matched donor lymphocytes. Scanty
lls/kg) CR achieved GVHD Grade
Status
at
analysis
NA Yes 2 A&W
NA Yes 4 Dead
NA Yes 1 A&W
NA — — Dead
NA — — A&W
NA Yes 3 Dead
No — — Dead
No — — Dead
No — — Dead
No — — Dead
No — — Dead
No — — Dead
No — — Dead
13  107 No — — Alive
No — — Dead
7, 107, 7.9  107 No — — Dead
No — — Dead
Temporary CR Yes 4 Dead
Hematological
response
— — Dead
No Yes 2 Dead
PR Yes 2 Dead
Yes Yes 3 Dead
No — — Dead
Yes Yes 1 Dead
No Yes 4 Dead
No Yes 2 Dead
106, 106, 1.9  Yes Yes 3 A&W
.7  108, 6  No Yes 1 Alive
CR, complete remission; GVHD, graft-versus-host disease; CML,
odysplastic syndrome; NA, not applicable; A&W, alive and well.(T ce
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105, 3.
.7  10
8
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Mismatched DLI after SCT 1299he literature. Kawano et al [14] reported on 4 patients
ho received transplants from HLA-mismatched do-
ors who received prophylactic DLI. All developed
cute GVHD (3 of 4 patients with GVHD grade 2)
nd all died 56-363 days after transplantation (death
ue to relapse, multiorgan failure, and GVHD).
lingebiel et al [15] reported their experience with
aploidentical SCT for childhood ALL. Ten of the 27
eported patients were treated with DLI (dose not
entioned) and 4 developed acute GVHD, maximum
rade 3. Outcome of these patients was not reported.
n another study, DLI was administered to recipients
f unrelated, T cell depleted, stem cell allografts, and
t was found that only HLA mismatching was associ-
ted with a higher incidence of grade 2 acute
VHD and mortality due to acute GVHD. Eighteen
f 20 (90%) recipients of mismatched and 53 of 86
62%) recipients of matched allografts developed
rade 2 GVHD (P  .01); of these, 9 (50%) recip-
ents of mismatched and 8 (15%) recipients of matched
tem cell allografts died of acute GVHD (P  .003).
either the GVHD risk group nor the number of T
ells infused was signiﬁcantly associated with acute
VHD. However, there was only 1 HLA locus mis-
atched in these patients [16]. Some other less infor-
ative case reports of recipients of mismatched DLI
xist in the literature [17-19].
In this report, we have described the Hadassah
xperience in a high-risk cohort of recipients of mis-
atched DLI, prophylactically and therapeutically,
ith hematologic malignancies. We have shown that
rophylactic DLI was signiﬁcantly more effective than
herapeutic DLI but carried a higher risk of GVHD.
s previously described for recipients of matched stem
ells and DLI [10,20,21], in patients who received
herapeutic DLI, a greater tumor burden lowered the
esponse. In parallel, possibly also partly explaining
his conclusion was the observation that a greater
umor burden lowered the risk of GVHD. Other
ossible explanations for this phenomenon is a down-
egulation of antihost alloreactivity caused by tumor
ells by acquired tolerance of allogeneic minor histo-
ompatibility antigens [22] or the presence of apopto-
ic cells (common in proliferating tumors) that induce
transforming growth factor -dependent regulatory
cell expansion [23]. Due to the small number of
atients with GVHD, we could not assess the effect of
nti-GVHD treatment on the GVL effect. GVHD
ppeared in 50% of patients. Surprisingly, a greater
LA mismatch lowered the risk of severe GVHD,
ith 3 of 19 DLIs in recipients of 3/6 mismatched
llografts and 16 of 29 DLIs in recipients of 5/6
ismatched allografts with similar median follow-
ps (187 and 192 days, respectively). Only 1 patient
howed evidence of graft rejection, thus excluding the
ossibility that the reason for lower risk of GVHD in
he other patients was rejection of lymphocytes. Death tas frequent and usually related to progression of the
asic disease rather than to DLI-induced complica-
ions. However, time to death, but not overall mor-
ality, was signiﬁcantly shorter with greater HLA
ismatch.
Our results justify the use of cell therapy after
ransplantation of mismatched stem cells in CML and
ML. Unfortunately, no success could be docu-
ented in our series with the limited number of pa-
ients with ALL. However, it should be remembered
hat development of GVHD after transplantation of
ismatched alloreactive T cells required immediate
nti-GVHD treatment, thus negating the GVL effects
nducible by alloreactive T cells. Because GVL effects
re time consuming even in patients with CML, which
s slowly progressing disease [24], whereas tumor pro-
ression in patients with relapsed chemoresistant ALL
s fast, it seems reasonable to apply DLI in ALL
rophylactically against a low tumor burden, or as
oon as the ﬁrst sign of molecular rather than overt
ematologic relapse is demonstrable, because, in prin-
iple, patients with ALL can respond to immunother-
py with DLI [10,21]. Due to the limited number of
atients, no analysis could have been performed re-
arding the effect of anti-GVHD treatment after DLI
when given) on GVL effects.
Based on the data and considering the cumula-
ive international experience, it appears that devel-
pment of safer cell therapy procedures with less
ggressive and more selective anticancer effects are
rgently required, particularly for recipients of mis-
atched stem cell allografts and other recipients of
cell depleted allografts. Such safer strategies
hould focus on more selective targeting of specif-
cally immune T cells and recombinant interleukin-
-activated natural killer cells [25-32] rather than
sing nonselective and hazardous nonspeciﬁc T cell
herapy or antibody-guided recombinant interleu-
in-2-activated lymphocytes [33]. The use of anti-
ancer effector cells devoid of GVHD capacity may
nable induction of effective GVL effects without
locking reactivity of alloreactive lymphocytes with
mmunosuppressive agents indicated to control
VHD. One promising approach currently under
nvestigations involves the use of activated, inten-
ionally mismatched CD3-depleted, CD56-positive
atural killer cells [27,28].
In conclusion, the development of safer and more
ffective cell-mediated immunotherapy for patients
ith leukemia resistant to all available anticancer mo-
alities remains a challenge. Maximizing antitumor
ffects and minimizing antihost reactivity remain the
old standard awaiting innovative methods to control
lloreactivity or, preferably, selective antitumor reac-
ivity of donor lymphocytes.
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